RAFE - ETF AI Analysis
Top Page
PIMCO RAFI ESG U.S. ETF (RAFE)
Rating:72Outperform
Price Target:―
Positive Factors
Strong Overall Performance
The ETF has shown strong gains so far this year and solid recent momentum, which suggests its strategy has been working well in the current market.
Healthy Top Holdings
Many of the largest positions, especially in health care and consumer staples, have delivered strong or steady performance, helping support the fund’s returns.
Broad Sector Diversification
The fund spreads its investments across several major sectors, which helps reduce the impact if any single industry experiences a downturn.
Negative Factors
Heavy U.S. Concentration
Almost all of the ETF’s assets are invested in U.S. companies, offering little protection if the U.S. market faces a prolonged slump.
Sector Tilts Toward Technology and Health Care
Large weights in technology and health care mean the fund’s performance is more sensitive to swings in these sectors than a more evenly balanced portfolio would be.
Mixed Results Among Top Tech Holding
One of the major technology positions has shown weak performance this year, which can drag on returns if that stock continues to lag.
RAFE vs. SPDR S&P 500 ETF (SPY)
AUM169.18M
RegionNorth America
Expense Ratio0.29%
Beta0.80
IssuerPIMCO
Inception DateDec 18, 2019
Dividend Yield1.44%
Asset ClassEquity
Index TrackedRAFI ESG US Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume7,087
30 Day Avg. Volume12,937
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
55.98Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering290
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
RAFE Summary
PIMCO RAFI ESG U.S. ETF (RAFE) is a fund that follows the RAFI ESG US Index, focusing on U.S. companies that score well on environmental, social, and governance (ESG) practices. It invests across the whole U.S. stock market, including large, mid, and small companies, with big positions in well-known names like Apple and Microsoft, plus major health care and financial firms. Someone might invest in RAFE to get broad diversification in U.S. stocks while supporting more responsible business practices and seeking long-term growth. A key risk is that the value of the ETF can go up and down with the overall stock market.
How much will it cost me?The PIMCO RAFI ESG U.S. ETF (RAFE) has an expense ratio of 0.29%, which means you’ll pay $2.90 per year for every $1,000 invested. This is slightly higher than average for ETFs because it is actively managed and incorporates ESG criteria, which require more research and oversight compared to passively managed funds. It’s a good option if you value sustainable investing and are comfortable with the slightly higher cost.
What would affect this ETF?The PIMCO RAFI ESG U.S. ETF could benefit from growing interest in ESG investing and the strong performance of its top holdings in technology and healthcare, sectors that often thrive during innovation and demographic shifts. However, potential risks include regulatory changes affecting ESG criteria, economic downturns impacting consumer spending, or rising interest rates that could pressure financial and cyclical sectors. Its focus on U.S. equities also makes it sensitive to domestic economic conditions and policy changes.
RAFE Top 10 Holdings
RAFE leans heavily on U.S. tech and health care, with Apple acting as a key engine thanks to its steadily rising share price and ongoing strength in services. Microsoft, while still a heavyweight, has been more of a mixed performer lately, losing some near-term momentum. On the health care side, UnitedHealth, Johnson & Johnson, and Merck are all pulling their weight, giving the fund a solid defensive backbone. Financials like JPMorgan add support, but overall this is a U.S.-centric, ESG-tilted portfolio where a handful of blue-chip names do most of the heavy lifting.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Apple | 5.15% | $8.70M | $4.57T | 35.69% | 79 Outperform | |
| Microsoft | 4.75% | $8.03M | $3.71T | -3.01% | 79 Outperform | |
| UnitedHealth | 3.26% | $5.52M | $369.69B | 61.96% | 72 Outperform | |
| Johnson & Johnson | 3.20% | $5.42M | $624.74B | 50.62% | 78 Outperform | |
| JPMorgan Chase | 2.62% | $4.42M | $950.35B | 24.25% | 72 Outperform | |
| Merck & Company | 2.13% | $3.61M | $317.57B | 63.59% | 80 Outperform | |
| Verizon | 1.97% | $3.32M | $195.52B | 8.92% | 81 Outperform | |
| Procter & Gamble | 1.84% | $3.11M | $338.88B | -5.51% | 69 Neutral | |
| Citigroup | 1.80% | $3.03M | $226.45B | 46.48% | 68 Neutral | |
| AT&T | 1.66% | $2.81M | $163.02B | -14.53% | 71 Outperform |
RAFE Technical Analysis
Positive
―
Price Trends
48.02
Positive
45.89
Positive
43.85
Positive
Market Momentum
0.55
Negative
67.74
Neutral
93.59
Negative
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For RAFE, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 48.80, equal to the 50-day MA of 48.02, and equal to the 200-day MA of 43.85, indicating a bullish trend. The MACD of 0.55 indicates Negative momentum. The RSI at 67.74 is Neutral, neither overbought nor oversold. The STOCH value of 93.59 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for RAFE.
RAFE Peer Comparison
Comparison Results
Performance Comparison
RAFE
PIMCO RAFI ESG U.S. ETF
49.83
11.27
29.23%
HLAL
Wahed FTSE USA Shariah ETF
―
―
―
VFMF
Vanguard U.S. Multifactor ETF
―
―
―
FDMO
Fidelity Momentum Factor ETF
―
―
―
AUSF
Global X Adaptive U.S. Factor ETF
―
―
―
BGDV
Bahl & Gaynor Dividend ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents